The present invention relates to methods and pharmaceutical compositions for the prevention and treatment of respiratory bacterial infections and more particularly of superinfection and acute exacerbation of chronic obstructive pulmonary disease with a therapeutically effective amount of an antagonist of IL-20 cytokines. Proof of concept has been achieved in mouse models with a mAb targeting IL20R